Trial Profile
Phase II, Single Arm, Open Label Trial for Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs HIL 214 (Primary)
- Indications Norovirus infections
- Focus Pharmacodynamics
- Sponsors Takeda
- 15 Oct 2019 Results published in the Journal of Infectious Diseases.
- 09 Feb 2017 New trial record